Isofol Medical AB (OSTO:ISOFOL) Total Operating Expense: kr57.52 Mil (TTM As of Mar. 2026)


OSTO:ISOFOL Isofol Medical AB OSTO:ISOFOL
30 GF Score
Price kr0.83
! 2 Warning Signs
View Full Analysis

What is Isofol Medical AB Total Operating Expense?

Isofol Medical AB OSTO:ISOFOL +2.22% 30 Total Operating Expense is kr57.52 Mil as of Mar. 2026. GuruFocus rates OSTO:ISOFOL with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Isofol Medical AB's Total Operating Expense for the three months ended in Mar. 2026 was kr15.60 Mil. Isofol Medical AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr57.52 Mil.

Isofol Medical AB Total Operating Expense Related Terms

Isofol Medical AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Isofol Medical AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Total Operating Expense Chart

Isofol Medical AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 226.87 180.34 42.41 47.21 55.98

Isofol Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.07 14.99 13.62 13.30 15.60
OSTO:ISOFOL
30GF Score
Isofol Medical AB OSTO:ISOFOL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Isofol Medical AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr57.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr57.52 Mil mean?
Isofol Medical AB (OSTO:ISOFOL) has a Total Operating Expense of kr57.52 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Isofol Medical AB and its competitors.
Is Isofol Medical AB's Total Operating Expense too high?
Isofol Medical AB's current Total Operating Expense is kr57.52 Mil. Overall, Isofol Medical AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Isofol Medical AB's Total Operating Expense compare to VRTX and REGN?
Isofol Medical AB's Total Operating Expense of kr57.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Isofol Medical AB and its competitors. Isofol Medical AB's current Total Operating Expense is kr57.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Isofol Medical AB stock overvalued right now?
Isofol Medical AB (OSTO:ISOFOL) has a current Total Operating Expense of kr57.52 Mil. The current Total Operating Expense is kr57.52 Mil. Isofol Medical AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Isofol Medical AB (OSTO:ISOFOL), the current Total Operating Expense is kr57.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Isofol Medical AB Business Description

Address Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
30GF Score

Get the complete analysis for OSTO:ISOFOL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.83
Price